Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Brain Neoplasms × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia, Myeloid, Acute 3 Primary Myelofibrosis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Anemia, Refractory, with Excess of Blasts 2 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Lymphoma, Extranodal NK-T-Cell 1 Hemoglobinuria, Paroxysmal 1 Hematologic Neoplasms 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Aplastic 1

Interventions

Temozolomide 147 Radiosurgery 106 Radiotherapy 91 Bevacizumab 88 Magnetic Resonance Spectroscopy 60 Carboplatin 46 Etoposide 32 pembrolizumab 30 Irinotecan 30 Cyclophosphamide 30 Surgical Procedures, Operative 29 Nivolumab 28 Erlotinib Hydrochloride 28 Radiation 26 Carmustine 25 Lomustine 23 Trastuzumab 21 Filgrastim 21 Cisplatin 21 Ipilimumab 20 Aminolevulinic Acid 19 Vincristine 18 Mental Status and Dementia Tests 18 Capecitabine 18 Topotecan 17 Specimen Handling 16 Pemetrexed 16 Imatinib Mesylate 14 Gefitinib 14 Thiotepa 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡